124 related articles for article (PubMed ID: 8863801)
1. Synthesis, resolution, and preliminary evaluation of trans-2-amino-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes and related derivatives as dopamine receptors ligands.
Claudi F; Cingolani GM; Di Stefano A; Giorgioni G; Amenta F; Barili P; Ferrari F; Giuliani D
J Med Chem; 1996 Oct; 39(21):4238-46. PubMed ID: 8863801
[TBL] [Abstract][Full Text] [Related]
2. Preparation and pharmacological characterization of trans-2-amino-5(6)-fluoro-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes as D2-like dopamine receptor agonists.
Di Stefano A; Sozio P; Cacciatore I; Cocco A; Giorgioni G; Costa B; Montali M; Lucacchini A; Martini C; Spoto G; Di Pietrantonio F; Di Matteo E; Pinnen F
J Med Chem; 2005 Apr; 48(7):2646-54. PubMed ID: 15801855
[TBL] [Abstract][Full Text] [Related]
3. 9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.
Ghosh D; Snyder SE; Watts VJ; Mailman RB; Nichols DE
J Med Chem; 1996 Jan; 39(2):549-55. PubMed ID: 8558526
[TBL] [Abstract][Full Text] [Related]
4. (+/-)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: novel dopamine D1 receptor antagonists.
Shah JH; Kline RH; Geter-Douglass B; Izenwasser S; Witkin JM; Newman AH
J Med Chem; 1996 Aug; 39(17):3423-8. PubMed ID: 8765528
[TBL] [Abstract][Full Text] [Related]
5. Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions.
Jutkiewicz EM; Bergman J
J Pharmacol Exp Ther; 2004 Dec; 311(3):1008-15. PubMed ID: 15292458
[TBL] [Abstract][Full Text] [Related]
6. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice.
Ralph RJ; Caine SB
J Pharmacol Exp Ther; 2005 Feb; 312(2):733-41. PubMed ID: 15494551
[TBL] [Abstract][Full Text] [Related]
7. Activity of N-(2-phenylethyl)-N-n-propyl-2-(3-hydroxyphenyl) ethylamine derivatives as dopamine receptor ligands.
Claudi F; Cardellini M; Di Stefano A; Giorgioni G; Cantalamessa F; Renò F; Balduini W
Drug Des Discov; 1994 Feb; 11(2):115-25. PubMed ID: 7915549
[TBL] [Abstract][Full Text] [Related]
8. Cooperative activation of D1-like and D2-like dopamine receptors in the nucleus accumbens shell is required for the reinstatement of cocaine-seeking behavior in the rat.
Schmidt HD; Pierce RC
Neuroscience; 2006 Oct; 142(2):451-61. PubMed ID: 16844308
[TBL] [Abstract][Full Text] [Related]
9. Topographical resolution of jaw movements mediated by cyclase- vs. non-cyclase-coupled dopamine D(1)-like receptors: studies with SK&F 83822.
Fujita S; Lee J; Kiguchi M; Uchida T; Cools AR; Waddington JL; Koshikawa N
Eur J Pharmacol; 2006 May; 538(1-3):94-100. PubMed ID: 16682023
[TBL] [Abstract][Full Text] [Related]
10. Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists.
Ryman-Rasmussen JP; Nichols DE; Mailman RB
Mol Pharmacol; 2005 Oct; 68(4):1039-48. PubMed ID: 15985612
[TBL] [Abstract][Full Text] [Related]
11. SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled dopamine D1-like receptors: behavioural topography.
O'Sullivan GJ; Roth BL; Kinsella A; Waddington JL
Eur J Pharmacol; 2004 Feb; 486(3):273-80. PubMed ID: 14985049
[TBL] [Abstract][Full Text] [Related]
12. Super-stereotypy I: enhancement of a complex movement sequence by systemic dopamine D1 agonists.
Berridge KC; Aldridge JW
Synapse; 2000 Sep; 37(3):194-204. PubMed ID: 10881041
[TBL] [Abstract][Full Text] [Related]
13. Stereoisomeric probes for the D1 dopamine receptor: synthesis and characterization of R-(+) and S-(-) enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-bromo analogue.
Neumeyer JL; Kula NS; Baldessarini RJ; Baindur N
J Med Chem; 1992 Apr; 35(8):1466-71. PubMed ID: 1533424
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of N-n-propyl-N-(2-arylethyl)-5-(1H-benzimidazol-2-thione)-eth ylamines and related compounds as potential dopaminergic ligands.
Soskic V; Dukić S; Dragović D; Joksimović J
Arzneimittelforschung; 1996 Aug; 46(8):741-6. PubMed ID: 9125270
[TBL] [Abstract][Full Text] [Related]
15. Failure of MK-801 to suppress D1 receptor-mediated induction of locomotor activity and striatal preprotachykinin mRNA expression in the dopamine-depleted rat.
Campbell BM; Kreipke CW; Walker PD
Neuroscience; 2006; 137(2):505-17. PubMed ID: 16289829
[TBL] [Abstract][Full Text] [Related]
16. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
Neal-Beliveau BS; Joyce JN
Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220
[TBL] [Abstract][Full Text] [Related]
17. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
[TBL] [Abstract][Full Text] [Related]
18. Negative feedback regulation of nigrostriatal dopamine release: mediation by striatal D1 receptors.
Saklayen SS; Mabrouk OS; Pehek EA
J Pharmacol Exp Ther; 2004 Oct; 311(1):342-8. PubMed ID: 15175419
[TBL] [Abstract][Full Text] [Related]
19. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.
Wirtshafter D; Osborn CV
Eur J Pharmacol; 2005 Dec; 528(1-3):88-94. PubMed ID: 16324697
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of 3-aryl-1-[(4-phenyl-1-piperazinyl)butyl]indazole derivatives and their affinity to 5-HT1A serotonin and dopamine D1 receptors.
Andronati S; Sava V; Makan S; Kolodeev G
Pharmazie; 1999 Feb; 54(2):99-101. PubMed ID: 10084155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
